Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

487.68 -1.30 (-0.27%)
Streaming Delayed Price Updated: 10:16 AM EDT, Jul 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
50 51 Next >
3 High-Flying Stocks That Could Soar Even More in 2024
These big winners could keep the momentum going. 
Via The Motley Fool
Market Whales and Their Recent Bets on VRTX Options
Via Benzinga
Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the... 
Via Benzinga
Exposures Product Safety
The Best Stock to Invest $1,000 in Right Now
This stock has what it takes to be a big winner. 
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
Via Benzinga
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 16 Analysts
Via Benzinga
A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings
Via Benzinga
Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock
Shares of Vertex have risen exponentially since last month. Crispr stock, though, is meandering. 
Via Investor's Business Daily
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Here's Why CRISPR Therapeutics Stock Rose 54% Last Year
Key regulatory developments sent this biotech stock higher. 
Via The Motley Fool
$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today
Via Benzinga
Down 88%, Could Editas Medicine Be a Good Investment Now?
The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles. 
Via The Motley Fool
My 3 Highest-Conviction Growth Stocks to Buy in 2024
Simply put, these stocks inspire confidence. 
Via The Motley Fool
3 Growth Stocks to Buy That Could Be Massive Long-Term Winners
These stocks appear to have what it takes to keep up their winning ways. 
Via The Motley Fool
3 Unstoppable Stocks to Buy in 2024
These stocks appear to be on a clear path to continued growth. 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week
These companies could stand out thanks to game-changing technology. 
Via The Motley Fool
Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. (NYSE: UBER) shares hit an all-time high on Thursda 
Via Benzinga
3 Stocks to Buy in the Booming Field of Gene Editing
As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains. 
Via InvestorPlace
Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)?
Reasonable growth and debt and a high ROIC for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX). 
Via Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
2 Red Flags for Bluebird Bio Stock
The biotech's struggles may continue. 
Via The Motley Fool
These 3 Stocks Have Beaten the S&P Average Return for Years and Are Likely to Continue That Trend
These winners seem likely to keep up their winning ways. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
Exposures Product Safety
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
The Ultimate Growth Stock to Buy With $1,000 Right Now
The stock, trading for about $60, has plenty of room to run. 
Via The Motley Fool
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
From Vertex Pharmaceuticals Incorporated
Via Business Wire
5 Top Stocks to Buy in January
Start the year off right by investing in these quality businesses. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
50 51 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.